Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
SAGE Sage Therapeutics, Inc. daily Stock Chart
SAGE [NASD]
Sage Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-13.51 Insider Own0.50% Shs Outstand51.79M Perf Week2.19%
Market Cap3.64B Forward P/E- EPS next Y-13.68 Insider Trans14.35% Shs Float50.87M Perf Month-3.94%
Income-670.00M PEG- EPS next Q-3.61 Inst Own- Short Float13.94% Perf Quarter-51.78%
Sales5.20M P/S700.96 EPS this Y-14.10% Inst Trans-6.16% Short Ratio5.70 Perf Half Y-57.26%
Book/sh20.91 P/B3.37 EPS next Y0.70% ROA-54.70% Target Price103.63 Perf Year-52.34%
Cash/sh21.67 P/C3.25 EPS next 5Y13.10% ROE-60.00% 52W Range56.50 - 193.56 Perf YTD-2.51%
Dividend- P/FCF- EPS past 5Y-60.30% ROI-45.60% 52W High-64.24% Beta2.42
Dividend %- Quick Ratio12.70 Sales past 5Y- Gross Margin96.50% 52W Low22.52% ATR2.39
Employees637 Current Ratio12.70 Sales Q/Q- Oper. Margin- RSI (14)47.29 Volatility2.76% 3.46%
OptionableYes Debt/Eq0.00 EPS Q/Q-32.30% Profit Margin- Rel Volume0.25 Prev Close70.38
ShortableYes LT Debt/Eq0.00 EarningsFeb 27 BMO Payout- Avg Volume1.24M Price69.22
Recom1.90 SMA201.25% SMA50-2.70% SMA200-49.82% Volume228,717 Change-1.64%
Feb-06-20Initiated Mizuho Neutral
Dec-06-19Reiterated RBC Capital Mkts Outperform $190 → $100
Dec-05-19Reiterated Guggenheim Buy $200 → $110
Dec-05-19Downgrade SunTrust Buy → Hold
Oct-30-19Initiated H.C. Wainwright Neutral $160
May-23-19Initiated Wedbush Outperform
Apr-25-19Initiated Jefferies Buy $195
Dec-14-18Initiated Wolfe Research Outperform
Oct-11-18Initiated Oppenheimer Outperform $170
Aug-07-18Reiterated Stifel Buy $198 → $239
Aug-06-18Initiated Piper Jaffray Overweight $206
Jun-06-18Initiated Ladenburg Thalmann Buy $230
Mar-26-18Resumed Canaccord Genuity Buy $210
Feb-26-18Initiated Morgan Stanley Overweight
Dec-08-17Reiterated Needham Buy $100 → $193
Dec-08-17Reiterated Canaccord Genuity Buy $140 → $191
Dec-07-17Reiterated Chardan Capital Markets Buy $140 → $225
Nov-10-17Upgrade Chardan Capital Markets Neutral → Buy $60 → $140
Nov-10-17Reiterated Needham Buy $86 → $100
Oct-06-17Resumed Goldman Buy $87
Feb-10-20 06:30AM  Sage Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020 Business Wire
Feb-04-20 04:30PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Feb-03-20 11:27AM  Andreas Halvorsen Trims Adaptive Biotechnologies Stake GuruFocus.com
Jan-17-20 08:40AM  An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 30% Undervalued Simply Wall St.
Jan-09-20 08:44AM  Hedge Fund Favorites vs. SAGE Therapeutics Inc (SAGE) In 2019 Insider Monkey
Jan-03-20 04:30PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Dec-29-19 03:24AM  Corporate Insiders Pull the Trigger on 3 Buy-Rated Stocks TipRanks
Dec-23-19 02:47PM  Investors flock to neuro drug makers after FDA approves new schizophrenia drug MarketWatch
06:30AM  Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Monday, January 13, 2020 Business Wire
Dec-19-19 03:07PM  Minerva shares fall on failed depression drug trial MarketWatch
Dec-16-19 11:28AM  Weekly CEO Buys Highlight GuruFocus.com
Dec-14-19 02:56PM  Notable Insider Buys In The Past Week: Enterprise Products Partners, PBF Energy, Sage Therapeutics Benzinga
Dec-12-19 08:15PM  HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened ACCESSWIRE +5.71%
10:38AM  Trade Alert: The Chief Scientific Officer Of Sage Therapeutics, Inc. (NASDAQ:SAGE), Albert Robichaud, Has Just Spent US$1.6m Buying Shares Simply Wall St.
Dec-11-19 08:01PM  HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened GlobeNewswire +8.50%
09:41AM  Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar Zacks
Dec-10-19 09:18PM  HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened PR Newswire
07:30AM  Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP) Business Wire
Dec-09-19 10:20AM  Sage Therapeutics (SAGE) in Focus: Stock Moves 7.1% Higher Zacks
06:20AM  SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Is Investigating the Officers and Directors of Sage Therapeutics, Inc. (SAGE) on Behalf of Shareholders ACCESSWIRE
Dec-06-19 03:00PM  Sell-Side Remains Optimistic On Sage Therapeutics Despite Depression Drug Disappointment Benzinga +7.11%
09:30AM  Sage Therapeutics Stock Collapsed After Depression-Drug Results. Analysts Say It Has Lost Enough Ground. Barrons.com
09:26AM  Sage Therapeutics' Depression Drug Fails in Study, Stock Down Zacks
Dec-05-19 08:31PM  Lost Money in Sage Therapeutics, Inc.? Business Wire -59.67%
04:18PM  6 Underperforming Stocks in Gurus' Portfolios GuruFocus.com
04:05PM  This Biotech Collapsed 60% After Its Depression Drug Unexpectedly Failed Investor's Business Daily
11:00AM  Sage Shareholders Face Classic Biotech Investor Dilemma Bloomberg
10:24AM  Sage Therapeutics Stock Is Cratering Because Its Depression Treatment Failed in a Key Trial Barrons.com
09:54AM  Shares of Cambridge biotech plunge as depression drug fails late-stage trial American City Business Journals
09:42AM  Sage Plunges as Key Depression Study Fails to Show Benefit Bloomberg
07:21AM  UPDATE 1-Sage's oral depression therapy fails in late-stage trial; shares plunge Reuters
07:18AM  Sage Therapeutics's stock plunges after depression treatment study fails primary endpoint MarketWatch
06:40AM  Sage's oral depression therapy fails in late-stage trial Reuters
06:30AM  Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder Business Wire
Dec-04-19 09:28AM  Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy ? Insider Monkey
Dec-03-19 04:30PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
09:57AM  Edited Transcript of SAGE earnings conference call or presentation 12-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-25-19 06:44PM  Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Sage Therapeutics, Inc. (SAGE) on Behalf of Shareholders Business Wire
Nov-20-19 06:10PM  These 3 Strong Buy Healthcare Stocks Have 40% Upside Or More, Says Cowen TipRanks
Nov-15-19 10:02AM  VistaGen's (VTGN) Major Depressive Disorder Drug Disappoints Zacks
Nov-12-19 06:31AM  Sage Therapeutics Announces Third Quarter 2019 Financial Results and Highlights Pipeline and Business Progress Business Wire
Nov-11-19 04:30PM  Sage Therapeutics to Present at the Stifel 2019 Healthcare Conference Business Wire
07:50AM  5 Biotech Stocks Set to Beat Q3 Earnings Estimates Zacks
Nov-05-19 06:00PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
12:01PM  Is Sage Therapeutics, Inc.'s (NASDAQ:SAGE) CEO Salary Justified? Simply Wall St.
Oct-30-19 01:49PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Sage Therapeutics, Inc.- SAGE GlobeNewswire
Oct-23-19 02:29PM  Drugmaker Alkermes cuts 160 jobs in effort to lower expenses American City Business Journals
Oct-20-19 06:06PM  Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy? Insider Monkey
Oct-14-19 03:42AM  Moving Average Crossover Alert: Sage Therapeutics Zacks
Oct-09-19 06:18PM  This Hedge Fund Returns 22% Annually, Here Are Its Latest Picks Insider Monkey
06:30AM  Sage Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 Business Wire
Oct-03-19 10:52AM  Sage Therapeutics Is Pointed Down So We Are In No Rush to Buy TheStreet.com
Oct-02-19 04:30PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
06:30AM  Sage Therapeutics to Participate in J.P. Morgan Executive Conference Call Series Business Wire
Sep-20-19 02:04PM  Here's Why We're Watching Sage Therapeutics's (NASDAQ:SAGE) Cash Burn Situation Simply Wall St.
01:10PM  Gilead, AbbVie Are Innovative, but May Be Underappreciated GuruFocus.com
Sep-05-19 04:31PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-04-19 05:05PM  Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive Disorder Business Wire
Sep-03-19 05:31PM  Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference Business Wire -6.34%
Aug-14-19 12:35PM  Edited Transcript of SAGE earnings conference call or presentation 6-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-06-19 06:30AM  Sage Therapeutics Announces Second Quarter 2019 Financial Results and Highlights Pipeline and Business Progress Business Wire
Aug-05-19 04:30PM  Sage Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference Business Wire
06:30AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jul-30-19 10:38AM  Earnings Preview: Sage Therapeutics (SAGE) Q2 Earnings Expected to Decline Zacks
Jul-24-19 06:30AM  Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline During Sage FutureCast Business Wire
Jul-23-19 01:53PM  Here's Why Marinus Pharmaceuticals Stock Is Collapsing Today Motley Fool
Jul-11-19 06:30AM  Sage Therapeutics to Report Second Quarter 2019 Financial Results on Tuesday, August 6, 2019 Business Wire
Jul-10-19 01:14PM  Spiros Segalas' Top 5 Buys of the 2nd Quarter GuruFocus.com
Jul-09-19 06:40AM  Is Sage Therapeutics's (NASDAQ:SAGE) 287% Share Price Increase Well Justified? Simply Wall St.
Jul-03-19 06:30AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jun-27-19 12:46PM  5 stocks trading at under $10 worth discovering MarketWatch +5.37%
06:30AM  Sage Therapeutics to Host Sage FutureCast Webcast Business Wire
Jun-19-19 08:12PM  Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy? Insider Monkey
Jun-18-19 06:30AM  Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference Business Wire
Jun-14-19 02:07PM  Why Sage Therapeutics' new Brier Creek center came at the perfect time American City Business Journals
08:53AM  Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSO (brexanolone) Injection Business Wire
Jun-06-19 09:17AM  Life sciences VC firm Third Rock raises $770M in its largest round ever American City Business Journals
Jun-05-19 06:30AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jun-04-19 06:30AM  Sage Therapeutics to Present at Goldman Sachs 40th Annual Global Healthcare Conference Business Wire
May-29-19 07:15PM  Sage Therapeutics Inc (SAGE) President & CEO Jeffrey M Jonas Sold $15 million of Shares GuruFocus.com
May-24-19 08:15PM  Sage Therapeutics Inc (SAGE) President & CEO Jeffrey M Jonas Sold $16.5 million of Shares GuruFocus.com
May-23-19 09:06AM  Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE PR Newswire
May-22-19 07:02AM  Are Investors Undervaluing Sage Therapeutics, Inc. (NASDAQ:SAGE) By 29%? Simply Wall St.
May-20-19 09:04AM  Ligand Grants Preclinical Candidate Rights to UK-based Firm Zacks
May-14-19 06:30AM  Sage Therapeutics to Present at 2019 RBC Capital Markets Global Healthcare Conference Business Wire
May-13-19 04:08PM  Edited Transcript of SAGE earnings conference call or presentation 2-May-19 12:00pm GMT Thomson Reuters StreetEvents
May-09-19 07:07AM  New England Venture Capital Association names 2019 NEVY Awards winners American City Business Journals
May-08-19 09:27AM  Small-Cap Stocks to Watch in May Motley Fool
May-07-19 04:01PM  Sage Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference Business Wire
May-06-19 04:45PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
May-02-19 06:30AM  Sage Therapeutics Announces First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress Business Wire
06:00AM  SAGE Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
05:20AM  These 6 biotech stocks are promising takeover targets MarketWatch
Apr-29-19 10:47AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Sage Therapeutics, Inc. GlobeNewswire
Apr-27-19 09:30AM  Sage Therapeutics' Zulresso is a big win for postpartum depression sufferers and maybe even the entire mental health community CNBC
09:16AM  How a failed epilepsy drug became a $34,000 postpartum cure CNBC Videos
Apr-26-19 06:10AM  Analysts point to potential Biogen M&A options after Alzheimer's failure American City Business Journals
Apr-24-19 10:45AM  Did Hedge Funds Drop The Ball On SAGE Therapeutics Inc (SAGE) ? Insider Monkey
Apr-18-19 04:30PM  Sage Therapeutics to Report First Quarter 2019 Financial Results on Thursday, May 2, 2019 Business Wire
Apr-03-19 06:30AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain; and SAGE-689, a novel GABAA receptor positive allosteric modulator that is in preclinical stage to treat acute and chronic CNS disorders. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
IGUCHI KIMICFO & TreasurerDec 10Option Exercise1.3650068029,261Dec 10 09:26 PM
Robichaud AlbertChief Scientific OfficerDec 09Option Exercise20.1215,743316,746111,400Dec 10 08:04 PM
IGUCHI KIMICFO & TreasurerDec 09Option Exercise1.3615,00020,40028,761Dec 10 09:26 PM
JONAS JEFFREY MPresident & CEODec 09Buy64.207,500481,50054,530Dec 10 08:04 PM
Robichaud AlbertChief Scientific OfficerDec 09Buy64.1625,0001,604,000136,400Dec 10 08:04 PM
JONAS JEFFREY MPresident & CEOSep 11Option Exercise0.454,6002,07047,030Sep 12 05:00 PM
Kanes StephenChief Medical OfficerSep 04Option Exercise0.456,0002,7008,292Sep 05 04:33 PM
FRATES JAMES MDirectorAug 15Option Exercise28.358,000226,80010,535Aug 16 04:04 PM
FRATES JAMES MDirectorAug 15Sale160.588,0001,284,6402,535Aug 16 04:04 PM
IGUCHI KIMICFO & TreasurerJul 25Option Exercise1.362,0002,72012,409Jul 25 06:02 PM
IGUCHI KIMICFO & TreasurerJul 17Option Exercise1.364,0005,44010,409Jul 17 04:02 PM
JONAS JEFFREY MPresident & CEOJul 16Option Exercise0.4527,00012,15039,115Jul 17 04:01 PM
JONAS JEFFREY MPresident & CEOMay 29Sale170.611,075183,40112,115May 29 04:01 PM
JONAS JEFFREY MPresident & CEOMay 28Option Exercise0.4535,73616,08197,851May 29 04:01 PM
JONAS JEFFREY MPresident & CEOMay 28Sale174.8384,66114,801,18913,190May 29 04:01 PM
JONAS JEFFREY MPresident & CEOMay 24Option Exercise0.4540,35618,160102,471May 24 06:24 PM
JONAS JEFFREY MPresident & CEOMay 24Sale175.0840,3567,065,54362,115May 24 06:24 PM
JONAS JEFFREY MPresident & CEOMay 23Option Exercise0.4553,90824,259116,023May 24 06:24 PM
JONAS JEFFREY MPresident & CEOMay 23Sale174.5153,9089,407,25362,115May 24 06:24 PM
Cloonan MichaelChief Business OfficerMay 22Option Exercise73.4325,0001,835,75025,461May 24 04:00 PM
Cloonan MichaelChief Business OfficerMay 22Sale175.0025,0004,375,000461May 24 04:00 PM
Cook Anne MarieSVP, GC & SecretaryMay 10Option Exercise29.8615,700468,83915,000May 10 04:31 PM
Cook Anne MarieSVP, GC & SecretaryMay 10Sale166.1415,0002,492,1000May 10 04:31 PM
FRATES JAMES MDirectorMay 06Option Exercise8.928,00071,36012,235May 06 06:21 PM
FRATES JAMES MDirectorMay 06Sale162.228,0001,297,7604,235May 06 06:21 PM
PAUL STEVEN MDirectorMar 21Sale161.047,8791,268,824122,400Mar 22 04:22 PM
PAUL STEVEN MDirectorMar 20Sale161.2956,6469,136,582130,279Mar 20 08:47 PM
PAUL STEVEN MDirectorMar 18Sale161.053,775607,977186,925Mar 20 08:47 PM
IGUCHI KIMICFO & TreasurerMar 08Option Exercise0.454,7232,1256,136Mar 11 05:03 PM
IGUCHI KIMICFO & TreasurerMar 01Sale156.9325,5634,011,6021,413Mar 01 04:46 PM
PAUL STEVEN MDirectorFeb 25Sale161.002,000322,00070,900Feb 27 05:48 PM
open in yahoo | open in reuters | open in google